Humacyte, Inc. (HUMA)

Humacyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	1.57	1.26	1.49
Revenue Growth (YoY)	-	-	23.91%	-15.29%	-75.90%
Cost of Revenue	88.6	76.55	63.26	61.34	54.08
Gross Profit	-88.6	-76.55	-61.7	-60.08	-52.59
Selling, General & Admin	25.8	20.39	22.88	21.13	12.01
Operating Expenses	25.8	20.39	22.88	21.13	12.01
Operating Income	-114.4	-96.94	-84.58	-81.21	-64.6
Interest Expense	-9.28	-6.6	-6.2	-4.35	-2.2
Interest & Investment Income	4.1	5.47	2.63	0.02	0.28
Other Non Operating Income (Expenses)	3.92	-0.26	0.42	0.06	-
EBT Excluding Unusual Items	-115.66	-98.33	-87.73	-85.48	-66.52
Merger & Restructuring Charges	-	-	-	-0.05	-
Other Unusual Items	-33.05	-12.44	75.77	59.06	-
Pretax Income	-148.7	-110.78	-11.97	-26.48	-66.52
Net Income	-148.7	-110.78	-11.97	-26.48	-66.52
Net Income to Common	-148.7	-110.78	-11.97	-26.48	-66.52
Shares Outstanding (Basic)	118	103	103	40	6
Shares Outstanding (Diluted)	118	103	103	40	6
Shares Change (YoY)	14.56%	0.36%	157.82%	593.25%	-71.34%
EPS (Basic)	-1.26	-1.07	-0.12	-0.66	-11.54
EPS (Diluted)	-1.26	-1.07	-0.12	-0.66	-11.54
Free Cash Flow	-99.69	-75.59	-72.18	-81.41	-55.89
Free Cash Flow Per Share	-0.84	-0.73	-0.70	-2.04	-9.69
Operating Margin	-	-	-5404.35%	-6429.77%	-4332.66%
Profit Margin	-	-	-764.54%	-2096.36%	-4461.70%
Free Cash Flow Margin	-	-	-4611.95%	-6445.76%	-3748.22%
EBITDA	-107.21	-89.22	-76.37	-72.97	-56.25
D&A For EBITDA	7.19	7.72	8.21	8.24	8.35
EBIT	-114.4	-96.94	-84.58	-81.21	-64.6

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q